Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

This modeling and simulation analysis was aimed at selecting doses of cinpanemab (BIIB054), a monoclonal antibody targeting aggregated α‐synuclein, for a phase II study in Parkinson’s disease (PD). Doses and regimens were proposed based on anticipated target concentration in brain interstitial fluid...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuchimanchi, Mita, Monine, Michael, Kandadi Muralidharan, Kumar, Woodward, Caroline, Penner, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499191/
https://www.ncbi.nlm.nih.gov/pubmed/32613752
http://dx.doi.org/10.1002/psp4.12538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499191/
https://www.ncbi.nlm.nih.gov/pubmed/32613752
http://dx.doi.org/10.1002/psp4.12538

Ejemplares similares